(888) 352-RUSH for help arranging an appointment.
Faculty Rank: Professor
Medical or Graduate Education:
University of Kerala Medical College, India
Henry Ford Hospital - Internal Medicine
Rush University Medical Center - Internal Medicine
Rush University Medical Center - Hematology/Oncology
Biologic therapy for cancer
Blood disorders, cancerous
Blood disorders, noncancerous
Bone marrow biopsy
Cutaneous T-cell lymphoma (CTCL)
Leukemias, acute and chronic
Myelodysplastic syndrome (MDS)
Targeted therapy for hematologic cancer
Clinical trials for the treatment of hematologic malignancies
Factors that predict response to therapy and prognosis
Monoclonal antibodies and experimental drug treatments for hematologic malignancies
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. Karmali R, Paganessi LA, Frank RR, Jagan S, Larson ML, Venugopal P, Gregory SA, Christopherson KW 2nd. J Leukoc Biol. 2013 2013 Jan 93(1):161-70. doi: 10.1189/jlb.0612301. Epub 2012 Nov 7. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Lancet Oncol. 2012 2012 Nov 13(11):1096-104. doi: 10.1016/S1470-2045(12)70436-9. Epub 2012 Oct 15. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma. Lai S, Venugopal P, Leslie W. Clin Adv Hematol Oncol. 2012 2012 Feb 10(2):134-6. No abstract available. Erdheim-Chester Disease. Liotta EM, Jhaveri MD, Fox JC, Venugopal P, Lewis SL. Arch Neurol. 2012 2012 Aug 27:1-2. doi: 10.1001/archneurol.2012.180. [Epub ahead of print] No abstract available. Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine. Jagan S, Paganessi LA, Frank RR, Venugopal P, Larson M, Christopherson KW 2nd. Adv Hematol. 2012 2012 2012:727683. doi: 10.1155/2012/727683. Epub 2012 Sep 23. A patient with necrobiotic xanthogranuloma presenting with an anterior mediastinal mass, plasma cell dyscrasia, and a lymphoproliferative disorder. Chen KY, Leslie W, Mahon B, Venugopal P. Clin Adv Hematol Oncol. 2011 2011 Sep 9(9):696-700. No abstract available. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P. Leuk Lymphoma. 2011 2011 Nov 52(11):2097-104. doi: 10.3109/10428194.2011.589549. Epub 2011 Jun 24. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA. Clin Lymphoma Myeloma Leuk. 2011 2011 Dec 11(6):467-74. doi: 10.1016/j.clml.2011.04.009. Epub 2011 Jun 22. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Nabhan C, Davis N, Bitran JD, Galvez A, Fried W, Tolzien K, Foss S, Dewey WM, Venugopal P. Cancer. 2011 2011 Apr 1 117(7):1490-7. doi: 10.1002/cncr.25603. Epub 2010 Nov 8. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Nabhan C, Davis N, Bitran JD, Galvez A, Fried W, Tolzien K, Foss S, Dewey WM, Venugopal P. Cancer. 2010 Nov 8 Clofarabine: a new treatment option for patients with acute myeloid leukemia. Larson ML, Venugopal P. Expert Opin Pharmacother. 2009 2009 Jun 10(8):1353-7. doi: 10.1517/14656560902997990. Review. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Schuster SJ, Venugopal P, Kern JC, McLaughlin P. Leuk Lymphoma. 2008 2008 Sep 49(9):1681-92. doi: 10.1080/10428190802216731. Review. Idiopathic hemophagocytic syndrome with a fulminant clinical course. Khandelwal A, Shah NB, Eichenseer P, Welker M, Miller I, Nangia J, Farhat M, Gimelfarb A, Kassar M, Batus M, Gezer S, Shammo J, Gregory S, Fung H, Venugopal P. Clin Adv Hematol Oncol. 2008 2008 Aug 6(8):587-90. Review. No abstract available.
To watch a brief video of Parameswaran Venugopal, MD, click the play button at the lower left corner of the video frame below.
(If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
I love working with the patients because I feel that I am able to do something which helps them. The medication I am giving is only one part of the whole treatment.
I usually tell my patients when I came out of my medical school I thought what is curing you is all the chemo that I give. Well as I get older, I realize [that] the drug I give is only part of the whole treatment. Even if I give the drug, the patient has to be determined to fight through it. And that’s a very important part of the whole treatment of the patient.